TY - JOUR
T1 - Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research
AU - O'Horo, John Charles
AU - Cerhan, James R.
AU - Cahn, Elliot J.
AU - Bauer, Philippe R.
AU - Temesgen, Zelalem
AU - Ebbert, Jon
AU - Abril, Andy
AU - Abu Saleh, Omar M.
AU - Assi, Mariam
AU - Berbari, Elie F.
AU - Bierle, Dennis M.
AU - Bosch, Wendelyn
AU - Burger, Charles D.
AU - Cano Cevallos, Edison J.
AU - Clements, Casey M.
AU - Carmona Porquera, Eva M.
AU - Castillo Almeida, Natalia E.
AU - Challener, Douglas W.
AU - Chesdachai, Supavit
AU - Comba, Isin Y.
AU - Corsini Campioli, Cristina G.
AU - Crane, Sarah J.
AU - Dababneh, Ala S.
AU - Enzler, Mark J.
AU - Fadel, Hind J.
AU - Ganesh, Ravindra
AU - De Moraes, Alice Gallo
AU - Go, John R.
AU - Gordon, Joel E.
AU - Gurram, Pooja R.
AU - Guru, Pramod K.
AU - Halverson, Erika L.
AU - Harrison, Michael F.
AU - Heaton, Heather A.
AU - Hurt, Ryan
AU - Kasten, Mary J.
AU - Lee, Augustine S.
AU - Levy, Emily R.
AU - Libertin, Claudia R.
AU - Mallea, Jorge M.
AU - Marshall, William F.
AU - Matcha, Gautam
AU - Meehan, Anne M.
AU - Franco, Pablo Moreno
AU - Morice, William G.
AU - O'Brien, Jennifer J.
AU - Oeckler, Richard
AU - Ommen, Steve
AU - Oravec, Caitlin P.
AU - Orenstein, Robert
AU - Ough, Natalie J.
AU - Palraj, Raj
AU - Patel, Bhavesh M.
AU - Pureza, Vincent S.
AU - Pickering, Brian
AU - Phelan, David M.
AU - Razonable, Raymund R.
AU - Rizza, Stacey
AU - Sampathkumar, Priya
AU - Sanghavi, Devang K.
AU - Sen, Ayan
AU - Siegel, Jason L.
AU - Singbartl, Kai
AU - Shah, Aditya S.
AU - Shweta, F. N.U.
AU - Speicher, Leigh L.
AU - Suh, Gina
AU - Tabaja, Hussam
AU - Tande, Aaron
AU - Ting, Henry H.
AU - Tontz, Russell C.
AU - Vaillant, James J.
AU - Vergidis, Paschalis
AU - Warsame, Mohamed Y.
AU - Yetmar, Zachary A.
AU - Zomok, Catherine (Cate) D.
AU - Williams, Amy W.
AU - Badley, Andrew D.
N1 - Funding Information:
Potential Competing Interests: Dr O’Horo has been paid consulting fees by Elsevier Inc and Bates College not directly pertaining to the presented work; Dr Cerhan has grant support from NanoString , Celgene , and Genentech not related to presented work; Dr Ebbert serves as a consultant for Nesmah; Dr Levy has received research grants (funds to the institution) for clinical trials related to critical illness and immunobiology of pediatric coronavirus disease 2019; Dr Tande has received honoraria from UpToDate.com, not related to this work; Dr Razonable has received research grants (funds to the institution) on clinical trials on interleukin 6 inhibitors and anti-spike monoclonal antibody against coronavirus disease 2019 (Roche and Regeneron); Dr Rizza has received research grants from Gilead Sciences for the clinical trial of Remdesivir ; Dr Badley is supported by grants from National Institute of Allergy and Infectious Diseases (grants AI110173 and AI120698 ), Amfar ( #109593 ), and Mayo Clinic (HH Shieck Khalifa Bib Zayed Al-Nahyan Named Professorship of Infectious Diseases) and is a paid consultant for Abbvie, is a paid member of the data and safety monitoring board for Corvus Pharmaceuticals, owns equity for scientific advisory work in Zentalis and Nference, and is founder and President of Splissen therapeutic; and Dr Libertin has received research grants (funds to the institution) on clinical trials on an antiviral compound and an engineered anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody (ViralClear and Humanigen).
Publisher Copyright:
© 2020 Mayo Foundation for Medical Education and Research
PY - 2021/3
Y1 - 2021/3
N2 - Objective: To report the Mayo Clinic experience with coronavirus disease 2019 (COVID-19) related to patient outcomes. Methods: We conducted a retrospective chart review of patients with COVID-19 diagnosed between March 1, 2020, and July 31, 2020, at any of the Mayo Clinic sites. We abstracted pertinent comorbid conditions such as age, sex, body mass index, Charlson Comorbidity Index variables, and treatments received. Factors associated with hospitalization and mortality were assessed in univariate and multivariate models. Results: A total of 7891 patients with confirmed COVID-19 infection with research authorization on file received care across the Mayo Clinic sites during the study period. Of these, 7217 patients were adults 18 years or older who were analyzed further. A total of 897 (11.4%) patients required hospitalization, and 354 (4.9%) received care in the intensive care unit (ICU). All hospitalized patients were reviewed by a COVID-19 Treatment Review Panel, and 77.5% (695 of 897) of inpatients received a COVID-19–directed therapy. Overall mortality was 1.2% (94 of 7891), with 7.1% (64 of 897) mortality in hospitalized patients and 11.3% (40 of 354) in patients requiring ICU care. Conclusion: Mayo Clinic outcomes of patients with COVID-19 infection in the ICU, hospital, and community compare favorably with those reported nationally. This likely reflects the impact of interprofessional multidisciplinary team evaluation, effective leveraging of clinical trials and available treatments, deployment of remote monitoring tools, and maintenance of adequate operating capacity to not require surge adjustments. These best practices can help guide other health care systems with the continuing response to the COVID-19 pandemic.
AB - Objective: To report the Mayo Clinic experience with coronavirus disease 2019 (COVID-19) related to patient outcomes. Methods: We conducted a retrospective chart review of patients with COVID-19 diagnosed between March 1, 2020, and July 31, 2020, at any of the Mayo Clinic sites. We abstracted pertinent comorbid conditions such as age, sex, body mass index, Charlson Comorbidity Index variables, and treatments received. Factors associated with hospitalization and mortality were assessed in univariate and multivariate models. Results: A total of 7891 patients with confirmed COVID-19 infection with research authorization on file received care across the Mayo Clinic sites during the study period. Of these, 7217 patients were adults 18 years or older who were analyzed further. A total of 897 (11.4%) patients required hospitalization, and 354 (4.9%) received care in the intensive care unit (ICU). All hospitalized patients were reviewed by a COVID-19 Treatment Review Panel, and 77.5% (695 of 897) of inpatients received a COVID-19–directed therapy. Overall mortality was 1.2% (94 of 7891), with 7.1% (64 of 897) mortality in hospitalized patients and 11.3% (40 of 354) in patients requiring ICU care. Conclusion: Mayo Clinic outcomes of patients with COVID-19 infection in the ICU, hospital, and community compare favorably with those reported nationally. This likely reflects the impact of interprofessional multidisciplinary team evaluation, effective leveraging of clinical trials and available treatments, deployment of remote monitoring tools, and maintenance of adequate operating capacity to not require surge adjustments. These best practices can help guide other health care systems with the continuing response to the COVID-19 pandemic.
UR - http://www.scopus.com/inward/record.url?scp=85101797266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101797266&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2020.12.006
DO - 10.1016/j.mayocp.2020.12.006
M3 - Article
C2 - 33673913
AN - SCOPUS:85101797266
SN - 0025-6196
VL - 96
SP - 601
EP - 618
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 3
ER -